TESARO Company Profile (NASDAQ:TSRO)

TESARO trades on the NASDAQ under the ticker symbol "TSRO."

TESARO, Inc. (NASDAQ:TSRO) announced its quarterly earnings results on Tuesday, August, 8th. The company reported ($2.82) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($2.52) by $0.30. The business had revenue of $29.50 million for the quarter, compared to analysts' expectations of $18.61 million. TESARO had a negative net margin of 1,301.19% and a negative return on equity of 104.00%. The firm's revenue for the quarter was down 17.6% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($1.28) EPS. View TESARO's Earnings History.

TESARO is scheduled to release their next quarterly earnings announcement on Wednesday, November, 1st 2017. View Earnings Estimates for TESARO.

21 brokers have issued 1 year target prices for TESARO's stock. Their predictions range from $120.00 to $236.00. On average, they expect TESARO's stock price to reach $171.10 in the next year. View Analyst Ratings for TESARO.

Here are some recent quotes from research analysts about TESARO stock:

• 1. Cann analysts commented, "These results are an analysis of the phase I/II TOPACIO study of niraparib plus pembrolizumab in combination with pembrolizumab (Keytruda) in patients with triple negative breast cancer (TNBC) or ovarian cancer. Safety and efficacy were presented from both the dose-finding portion as well as the dose-expansion portion of the study. We believe these data released today support a path forward for Tesaro in the TNBC setting with Zejula. TNBC is a particularly challenging setting. There are many studies from numerous drug sponsors underway and TNBC, but there is no established reference standard for this disease." (9/8/2017)
• 2. FBR & Co analysts commented, "We received our first data snapshot from the RX-3117 Phase 2a study in advanced muscle invasive bladder cancer at ASCO this weekend with data coming from 10 patients in stage 1 of the study. The study achieved the predefined efficacy criteria (two of ten patients achieving a PFS of at least four months or a partial or complete tumor response), where 22% of patients have experienced PFS for a minimum of six months. One of the two aforementioned patients is still on study, achieving 175 days of stable disease. While only stage 1 of this study, we believe it is important to point out that patients who have reached this stage of disease are usually limited to palliative or best supportive care." (6/5/2017)
• 3. Cowen and Company analysts commented, "TSRO reported 1Q financials, provided a pipeline update and commented on Zejula’s." (5/11/2017)
• 4. According to Zacks Investment Research, "Tesaro, Inc. is an oncology-focused biopharmaceutical company for cancer patients. The Company's product portfolio consists of Rolapitant, a neurokinin-1 receptor antagonist for the prevention of chemotherapy induced nausea and vomiting, TSR-011, an orally available anaplastic lymphoma kinase inhibitor for the treatment of non-small cell lung cancer and other cancer indications, and Niraparib, an orally active and potent poly (ADP-ribose) polymerase inhibitor for the treatment of patients with solid tumors. Tesaro, Inc. is based in Waltham, Massachusetts. " (3/31/2017)
• 5. Wedbush analysts commented, "With first-mover advantage in the maintenance setting, a lack of requirement for a diagnostic, as well clinical data that is at least as good as Lynparza in gBRCA patients, we continue to believe that TSRO remains an attractive acquisition candidate." (3/28/2017)

Some companies that are related to TESARO include Kite Pharma (KITE), Exelixis (EXEL), BIOVERATIV INC (BIVV), bluebird bio (BLUE), Neurocrine Biosciences (NBIX), Juno Therapeutics (JUNO), Clovis Oncology (CLVS), BeiGene (BGNE), Agios Pharmaceuticals (AGIO), Spark Therapeutics (ONCE), AveXis (AVXS), Sarepta Therapeutics (SRPT), GW Pharmaceuticals PLC (GWPH), Axovant Sciences Ltd (AXON), Loxo Oncology (LOXO), Prothena Corporation PLC (PRTA), China Biologic Products (CBPO) and Halozyme Therapeutics (HALO).

TESARO's management team includes the folowing people:

• David M. Mott, Independent Chairman of the Board
• Mary Lynne Hedley Ph.D., President, Chief Operating Officer, Director
• Leon O. Moulder Jr., Chief Executive Officer, Director
• Timothy R. Pearson, Chief Financial Officer, Executive Vice President
• Jeffrey H. Hanke Ph.D., Executive Vice President - Research and Development, Chief Scientific Officer
• Joseph L. Farmer, Senior Vice President, General Counsel, Secretary
• Grant C. Bogle, Senior Vice President, Chief Commercial Officer
• Martin H. Huber M.D., Senior Vice President and Chief Medical Officer
• Lawrence M. Alleva, Independent Director
• James O. Armitage M.D., Independent Director

TESARO's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include NEA Management Company LLC (19.08%), FMR LLC (14.29%), BlackRock Inc. (6.69%), Vanguard Group Inc. (5.53%), InterWest Venture Management Co (3.75%) and Franklin Resources Inc. (3.48%). Company insiders that own TESARO stock include Arnold L Oronsky, Edward C English, Enterprise Associates 13 L New, Grant C Bogle, James O Armitage, Jeffrey H Hanke, Martin H Jr Huber, Mary Lynne Hedley and Orlando Oliveira. View Institutional Ownership Trends for TESARO.

TESARO's stock was sold by a variety of institutional investors in the last quarter, including Franklin Resources Inc., FMR LLC, Northern Trust Corp, Federated Investors Inc. PA, Lord Abbett & CO. LLC, Neuberger Berman Group LLC, Schwab Charles Investment Management Inc. and Van ECK Associates Corp. Company insiders that have sold TESARO stock in the last year include Edward C English, Grant C Bogle, James O Armitage, Martin H Jr Huber, Mary Lynne Hedley and Orlando Oliveira. View Insider Buying and Selling for TESARO.

TESARO's stock was bought by a variety of institutional investors in the last quarter, including Janus Henderson Group PLC, PointState Capital LP, Pioneer Investment Management Inc., BlackRock Inc., State Street Corp, Tobam, Fiera Capital Corp and Pictet Asset Management Ltd.. Company insiders that have bought TESARO stock in the last two years include Arnold L Oronsky and Enterprise Associates 13 L New. View Insider Buying and Selling for TESARO.

Shares of TESARO can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of TESARO stock can currently be purchased for approximately $119.04.